---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-25-000109"
form_type: "8-K/A"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:47:48.225853+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q3 revenue $205.7M (-4% YoY); adjusted EPS $0.00; reaffirms FY2025 guidance

## Summary
- Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M headwinds (UNH GeneSight loss, EndoPredict divestiture).
- GAAP net loss $27.4M ($0.29 loss); adjusted EPS $0.00; adjusted EBITDA $10.3M.
- Hereditary cancer testing volume +11% YoY; GeneSight revenue -19% YoY due to UnitedHealthcare coverage change.
- Entered strategic CDx collaboration with SOPHiA GENETICS for liquid biopsy companion diagnostics.
- Reiterates FY2025 revenue $818-828M, gross margin 69.5-70%, adjusted EBITDA $27-33M.

## SEC filing metadata
- accession: 0000899923-25-000109
- form_type: 8-K/A
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992325000109/0000899923-25-000109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992325000109/mygn-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-25-000109
- JSON: https://secwatch.observer/filing/0000899923-25-000109.json
- Plain text: https://secwatch.observer/filing/0000899923-25-000109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.